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Abstract 
The globally significant human pathogen group A Streptococcus (GAS) sequesters the host protease 
plasmin to the cell surface during invasive disease initiation. Recent evidence has shown that localized 
plasmin activity prevents opsonization of several bacterial species by key components of the innate 
immune system in vitro. Here we demonstrate that plasmin at the GAS cell surface resulted in 
degradation of complement factor C3b, and that plasminogen acquisition is associated with a decrease 
in C3b opsonization and neutrophil-mediated killing in vitro. Furthermore, the ability to acquire cell surface 
plasmin(ogen) correlates directly with a decrease in C3b opsonization, neutrophil phagocytosis, and 
increased bacterial survival in a humanized plasminogen mouse model of infection. These findings 
demonstrate that localized plasmin(ogen) plays an important role in facilitating GAS escape from the 
host innate immune response and increases bacterial virulence in the early stages of infection. 
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The globally significant human pathogen group A Streptococcus (GAS) sequesters the host 
protease plasmin to the cell surface during invasive disease initiation. Recent evidence has 
shown that localized plasmin activity prevents opsonisation of several bacterial species by 
key components of the innate immune system in vitro. Here we demonstrate that plasmin at 
the GAS cell surface resulted in degradation of complement factor C3b, and that plasminogen 
acquisition is associated with a decrease in C3b opsonization and neutrophil-mediated killing 
in vitro. Furthermore, the ability to acquire cell surface plasmin(ogen) correlates directly with 
a decrease in C3b opsonisation,  neutrophil phagocytosis , and increased bacterial survival in 
a humanized plasminogen mouse model of infection. These findings demonstrate that 
localized plasmin(ogen) plays an important role in facilitating GAS escape from the host 
innate immune response and increases bacterial virulence in the early stages of infection. 
 
Introduction 
The Gram-positive bacterium group A Streptococcus (GAS, Streptococcus pyogenes) is 
responsible for over 600 million infections each year [1]. Superficial infections including 
pharyngitis and impetigo follow from GAS colonizing epithelial surfaces of the upper 
respiratory tract and skin, while further dissemination into sterile tissue sites can lead to life-
threatening conditions such as necrotizing fasciitis and streptococcal toxic shock syndrome 
[2]. The high disease burden of GAS underlies a need to identify key mechanisms of 





Subversion of the host plasminogen activation system is central to the initiation of invasive 
infection by GAS [3-5]. Plasminogen circulates as a 92 kDa zymogen in blood and 
extracellular fluids at an approximate concentration of 2 μM [6]. Plasminogen can be 
converted to plasmin by the host activators urokinase plasminogen activator (uPA) and tissue 
plasminogen activator (tPA), or bacterial activators including the secreted GAS protein 
streptokinase. GAS expresses multiple cell surface receptors for plasmin(ogen), including 
glyceraldehyde-3-phosphate dehydrogenase, surface α-enolase and the plasminogen binding 
M-like proteins (PAM, Prp) [7]. Once localized to the bacterial surface, the broad spectrum 
protease plasmin is thought to facilitate degradation of fibrin clots and extracellular matrix 
components, leading to bacterial dissemination. More recently, plasmin mediated evasion of 
host immunity has emerged as a key mechanism in bacterial pathogenesis [7,8]. 
The complement system is a critical component of the innate immune response against 
bacterial pathogens and involves the coordinated action of over 30 proteolytic plasma 
enzymes [9]. Activation of the complement cascade occurs via three distinct routes, 
comprising the classical, alternate and lectin pathways. Central to each of these pathways is 
the cleavage product of C3 convertase, C3b, a key opsonin that binds to microbial surfaces. 
Phagocytes such as macrophages and neutrophils recognise opsonized bacteria via specific 
complement receptors, leading to phagocytosis and microbial killing.  
Plasmin has been to shown to degrade C3b, and plasmin-mediated C3b degradation by 
bacteria has been observed in vitro [10,11]. In the present study, we demonstrate for the first 
time that GAS-localized plasmin degrades human C3b, and that cell-surface plasminogen 
acquisition correlates with decreased C3b deposition and resistance to complement mediated 





correlates with reduced C3b deposition, C3b mediated neutrophil killing and increased 





Materials and Methods 
Bacterial strains and culture conditions 
The clinical GAS strain NS88.2 was isolated from a case of invasive blood infection and has 
been described previously [12]. The isogenic derivative NS88.2prp, which expresses a 
mutated M protein attenuated for plasminogen binding has been described elsewhere [5]. A 
precise, in-frame allelic replacement of the streptokinase (ska) gene with cat encoding 
chloramphenicol transferase was created in GAS wild-type strain NS88.2 using established 
methods [13], and the resulting strain designated NS88.2∆ska. Phenotypic properties of this 
isogenic mutant strain (i.e. growth rate, capsule production and streptokinase secretion) were 
confirmed as described in [13] . To facilitate detection of GAS using flow cytometry, the 
green fluorescence protein (GFP) expression vector pDCermGFP, containing the e-gfp gene 
placed behind the constitutive tet, cat and erm promoters [14] was transformed into GAS 
strains NS88.2, NS88.2prp and NS88.2∆ska using standard GAS electroporation techniques 
[15]. Streptococci were routinely cultured under static conditions at 37°C in Todd-Hewitt 
broth (Difco, Australia) supplemented with 1% (w/v) yeast extract (THBY), or grown on 
horse blood agar (HBA) (Oxford, UK). In all assays, GAS cultures were grown to an optical 
density of 0.5 at 600nm. Escherichia coli were propagated in Luria Bertani (LB) broth or on 
LB agar at 37°C. For antibiotic selection, erythromycin was supplemented at 2 µg/mL for 
GAS and 500 µg/mL for E. coli. 
Streptokinase-mediated cell surface plasmin acquisition 
To accumulate plasmin at the GAS cell surface, GAS were cultured in the presence of 100 
nM human Glu-plasminogen (Haemotologic Technologies Inc., Essex Junction, VT) for 2 h 





secreted bacterial plasminogen activator, streptokinase. Glu-plasminogen was omitted from 
negative controls. Bacteria were pelleted by centrifugation for 10 min at 14,000 x g and 
washed twice in phosphate buffered saline (PBS) to remove unbound plasmin(ogen). Cells 
were then resuspended in 45 µL PBS prior to the addition of the plasmin-specific substrate 
Spectrozyme PL (American Diagnostica, Stamford, CT) to a final concentration of 0.5 mM. 
Cell surface plasmin activity was measured at 405 nm using a SpectraMax® plate reader 
(Molecular Devices).  
Cell surface plasmin acquisition in plasma 
Cell surface plasmin acquisition in human or mouse plasma was performed essentially as 
described previously [4] in fresh plasma containing 10 mM sodium-citrate. Briefly, bacteria 
were resuspended in plasma or PBS for 10 min at 37°C. After two washes with PBS, plasmin 
bound to the GAS surface was measured as described above.  
Cell surface plasminogen acquisition in plasma  
Binding of plasminogen to the GAS cell surface was detected as described previously. 
Brifely, following incubation of GAS in either human or mouse plasma from mice expressing 
the human plasminogen transgene, plasminogen was eluted from the bacterial cell surface 
using 100 mM Glycine-HCl (pH 2.0) [5].The eluent was screened for the presence of 
plasminogen by western blot analysis using rabbit anti human plasminogen (Calbiochem), 
goat anti -rabbit IgG HRP conjugate (Invitrogen), and enhanced chemiluminescence  
detection. 





The ability of plasmin to degrade C3b was performed according to the methods described by 
Rooijakkers et al. [11]. Prior to an overnight incubation at 37°C, 1 µg human C3b 
(Calbiochem, San Diego, CA) was incubated in PBS, or PBS containing either 100 nM Glu-
plasminogen, 100 nM streptokinase, 100 nM human plasmin (Haemotologic Technologies 
Inc.) or 100 nM Glu-plasminogen and 100 nM streptokinase. Following centrifugation, 
supernatant samples were collected and separated on a 10 % (w/v) SDS-PAGE gel under 
reducing conditions. Proteins were transferred onto a nitrocellulose membrane and post-
transfer, the membrane was blocked overnight in 10% (w/v) skim milk (Difco, Australia). 
C3b was detected using polyclonal goat antisera raised against human C3 (Calbiochem), 
followed by HRP-conjugated rabbit anti-goat IgG (Invitrogen, Carlsbad, CA) for 1 h at room 
temperature. Protein bands were visualised using enhanced chemiluminescence reagents 
(Pierce Biotchnology, Rockford, Ill., USA) following the manufacturer's instructions. To 
assess the impact of GAS cell surface plasmin activity on C3b, GAS with or without cell-
associated plasmin was incubated overnight with 0.5 µg human C3b at 37°C in a total volume 
of 10 µL and C3b degradation visualised as above.  
Characterisation of C3b deposition in vitro 
The influence of fluid- phase plasmin on C3b deposition was analysed by whole-cell ELISA 
according to the methods of Rooijakkers et al. [11]. Bacteria were resuspended in   PBS, and 
coated onto a 96-well microtiter plate and incubated for 2 h at 37°C, followed by incubation 
overnight at 4°C. Following each incubation step, wells were washed three times with PBS 
containing 0.05% (v/v) Tween-20 (PBST). Blocking was performed with 100 µL of 1% (w/v) 
bovine serum albumin (BSA) for 1 h at 37°C. Fresh human plasma was then serially diluted 
1:3 across the plate in 1% BSA and incubated at 37°C for 20 min. Negative controls did not 





1% BSA was added to each well, and the plate incubated for 1 h at 37°C. Overnight 
incubation at 37 °C was conducted after the addition of 50 µL of goat anti-human C3 serum, 
followed by HRP-conjugated rabbit anti-goat IgG for 1 h at 37°C. After the addition of 50 µL 
substrate solution (8 mM Na2HPO4 adjusted to pH 5.0 with solid citric acid containing 0.4% 
[w/v] o-Phenylenediamine and 4% [v/v] H2O2), reactions were stopped with 1 M HCl and 
C3b deposition was visualised spectrophotometrically at 490 nm. Coating of GAS to the 
microtiter plate was confirmed using rabbit anti-M antisera [16], followed by detection with 
HRP-conjugated goat anti-rabbit IgG.  
To examine the effects of GAS cell surface plasmin acquisition on C3b deposition at the 
bacterial surface, fluorescent GAS were incubated in 100 µL of 50% human  or mouse  
plasma diluted in PBS for 10 min at 37°C. Following two washes with PBS, non-specific 
binding sites were blocked by incubating bacteria with human IgG (Invitrogen) diluted 1:500 
in PBS for 30 min on ice. Bacteria were washed twice and resuspended in 200 µL PBS, 
which was subsequently divided into two 100 µL samples. To detect surface-bound C3b, 
samples were then incubated with 0.2 µg of phycoerythrin (PE)-conjugated anti-human C3 
monoclonal antibody (Cederlane Laboratories Ltd.), or 0.2 µg of PE-labelled mouse IgG1 
isotype control (Cederlane Laboratories Ltd.) and  light-protected for 1 h on ice. For flow 
cytometry analysis, bacterial cells were resuspended in 100 µL PBS, fixed with 100 µL 4% 
(w/v) PFA and made up to a final volume of 400 µL PBS. Alternatively, opsonized bacteria 
were incubated with Spectrozyme PL to confirm the presence or absence of cell surface 
plasmin activity. Gating parameters for GFP-expressing GAS were determined using a scatter 
plot, and the amount of C3 attached to the bacterial surface was expressed as a percentage of 





cytometer (Franklin Lakes, NJ) set to detect GFP and PE fluorescence. Data were analysed 
with FlowJo7 8.4.6 (TreeStar Inc. Ashland, OR). 
Homozygous humanized plasminogen mice 
Male and female, heterozygous, transgenic humanised plasminogen mice (AlbPLG1+/-) were 
crossed to generate a homozygous line. Resultant litters were genotyped following a simple 
yet efficient DNA extraction from ear cuttings. Briefly, the tissue samples were incubated in 
100 µL of lysis buffer (100 mM Tris pH 7.5, 5 mM EDTA, 200 mM NaCl, 0.5% [v/v] 
Tween-20, 15 µL Proteinase K [1 mg/ml]) at 56°C for 4 hours. The DNA samples were then 
used directly as templates for detection of the transgene by PCR. Heterozygous and 
homozygous mice are indistinguishable by standard PCR analysis, thus we performed qRT-
PCR to identify progeny from the cross with higher levels of the human plasminogen 
transgene with the primers PlgA (5’-CAGCTCCCTGTGATTGAGAA-3’) and PlgB (5’-
GAAGTGACTCCTTGTAAAATG-3’). Two male and two female individual mice displayed 
elevated transgene levels for human plasminogen and were subsequently backcrossed to 
wild-type C57BL/6J mice for confirmation of the homozygous genotype. Transgenic parents 
that gave rise to 100 % heterozygous offspring (n ≥ 6 per litter), determined by standard PCR 
(3), were confirmed to be homozygous (AlbPLG1+/+) for the human plasminogen transgene 
and retained to establish the breeding colony. 
Characterisation of GAS virulence in homozygous mice 
Mouse plasma was assayed for mouse plasminogen using a mouse- plasminogen specific 
ELISA kit (CSB-EL018188MO), according to the manufacturers instructions (CUSABIO, 
China).  Mouse plasma was assayed for plasminogen activation using purified recombinant 





sample was mixed with 100 nM streptokinase in assay buffer (10 mM HEPES, 150 mM 
NaCl, 0.01% [v/v] Tween-20; pH 7.4) at 37°C for 20 min. Substrate S-2251 (Chromogenix, 
Sweden) was added to a final concentration of 600 µM and plasmin activity was monitored 
over time by measuring the absorbance at 405 nM. Absorbance was plotted against time, and 
activity rates were determined from the linear portion of the curve. A background activity, 
determined for each plasma sample in the absence of streptokinase, was subtracted from the 
final rate. The amount of plasmin activity generated in each plasma sample was determined 
using a standard curve of preformed (20 min) group C streptococcal streptokinase/human 
Glu-plasminogen complex serially diluted in assay buffer. To assess the level of activatable 
human plasminogen, human and mouse plasma samples were diluted 1:10 in assay buffer (10 
mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4).  Human plasminogen present in the 
plasma samples was converted to plasmin by the addition of 5 nM streptokinase from group 
C streptococcal strain H46A [17] and incubation at RT for 15 min.  Plasmin activity was then 
measured by adding the plasmin specific substrate, S2251 (500 µM) and monitoring the 
change in absorbance at 405 nm over time using a SpectraMax Plus 384 spectrophotometer 
(Molecular Devices, Sunnyvale, CA, USA).  The plasmin activity, expressed as a percentage 
of human plasma was calculated by dividing the A405/min of mouse plasma by the A405/min 
of human plasma and then multiplying by 100.  All reactions were linear over the initial 20 
min of the reaction.To confirm GAS virulence in this model, cohorts of 10 age and sex 
matched mice (AlbPLG1+/- or AlbPLG1+/+) were infected subcutaneously with GAS as 
described previously [5]. The ability of GAS to acquire cell surface plasmin in plasma from 
different mouse lines was determined as described above.  





Sex matched transgenic homozygous mice expressing human plasminogen aged between 8 
and 10 weeks were intradermally inoculated with 1 x 108 CFU of eGFP-expressing NS88.2 (n 
= 8), NS88.2prp (n = 4) or NS88.2∆ska (n = 4) into the right and left shaved flanks. Mice 
were sacrificed by CO2 asphyxiation 4 h thereafter, and the intradermal layer lavaged twice 
with 500 µL of sterile saline. C3b deposition on recovered GAS was assessed by flow 
cytometry described above. Supernatants collected from the right and left flanks of each 
mouse were pooled to increase the yield of bacterial cells.  To determine the level of GAS 
uptake by neutrophils, cells recovered from the flank were  blocked  with Fc Block (anti-
mouse CD16/32; Biolegend) , A cocktail of appropriately diluted Ly6C, Ly6G and CD45 
(Biolegend) was added in FACS buffer (DPBS, 0.2% BSA, 1 mM NaN3) followed by 
incubation on ice for 20 minutes. The cells were then washed and resuspended in 0.5 ml of 
FACS buffer.  Samples were then acquired on a BD LSR II flow cytometer. 
 Alternatively, the ability of NS88.2 (n = 6), NS88.2prp (n = 5) and NS88.2∆ska (n = 5) to 
survive in vivo was determined by pelleting the collected bacteria at 14,000 x g for 10 min. 
Following serial dilutions performed in sterile Milli-Q water, bacteria were subsequently 
plated onto HBA overnight at 37°C and the number of bacterial colonies enumerated. 
C3b-mediated polymorphonuclear leukocyte (PMN) killing assay 
GAS strains were opsonized with autologous human plasma for 10 min at 37°C. Following 
two washes with PBS, bacteria (2 x 104 CFU) were diluted in RPMI media (Invitrogen) 
supplemented with 2% heat inactivated plasma, and incubated with polymorphonuclear 
leukocytes (2 x 105) isolated from fresh human blood as described by Hollands et al.[8]. The 
reaction mixture was then plated onto HBA and the CFU enumerated via colony counting 





identical conditions in the absence of  PMNs. GAS survival was calculated as a percentage of 
GAS surviving following PMN incubation compared with growth controls.  To confirm that 
the killing of GAS was complement-mediated, bacteria were alternatively opsonized with 3% 
(w/v) C3-depleted human plasma (Calbiochem). GAS cell surface plasmin acquisition assays 
were also performed in parallel to confirm levels of cell surface plasmin. 
Statistical Analysis 
Differences in the level of plasmin acquisition at the GAS cell surface were determined using 
the Student’s t-test. All other data were analysed using one-way analysis of variance with 
Tukey’s multiple comparison test. Data sets were considered statistically significant at P < 
0.05. All analysis was performed using GraphPad Prism version 4.02 (GraphPad software 
Inc.).  
Ethics Approval 
Animal studies complied with the Guidelines for the Care and Use of Laboratory Animals 
(National Health and Medical Research Council, Australia) and were approved by the 
University of Wollongong Animal Ethics Committee (AE11/04 and AE11/09). Collection of 
blood was performed with the approval of the University of Wollongong Human Ethics 
committee (HE08/250). Volunteers provided informed consent prior to donating blood 






Plasmin at the GAS cell surface degrades C3b 
GAS streptokinase mediates plasminogen activation by the formation of a 1:1 stoichiometric 
complex with plasminogen, resulting in a complex with plasmin and plasminogen activator 
activity [18]. To confirm that plasmin generated by streptokinase could degrade C3b, as 
reported for plasmin generated using host activators, we employed a solution phase 
degradation assay, followed by western blot analysis. Streptokinase generated plasmin 
degraded C3b, whereas no degradation was seen in the presence of either streptokinase or 
plasminogen alone (Fig. 1A). To further assess the ability of plasmin sequestered to the GAS 
cell surface to degrade C3b, we employed a wild-type parent GAS strain (NS88.2) and its 
isogenic mutants abrogated for either cell surface plasmin acquisition (NS88.2prp) [5] or 
streptokinase expression (NS88.2∆ska; Fig. S1). C3b degradation by GAS was dependent on 
the presence of cell surface plasmin. Following pre-incubation with plasminogen, wild-type 
NS88.2 degraded C3b; however, incubation of C3b with NS88.2prp or NS88.2∆ska, which 
do not accumulate cell surface plasmin activity under these conditions, did not result in 
detectable C3b degradation (Fig. 1B). Likewise, GAS strains were not able to degrade C3b 
without a source of cell surface plasmin activity (Fig. 1B). These data clearly demonstrate 
that streptokinase generated plasmin, and plasmin localized to the GAS cell surface, mediate 
complement C3b degradation.  
Plasmin(ogen) reduces C3b deposition on GAS in vitro 
To determine if fluid-phase plasmin was able to deplete C3b from the bacterial surface, C3b 
deposition on the GAS cell surface in the presence and absence of plasmin was measured via 





in 33% human plasma. The addition of exogenous plasmin post-opsonization resulted in a 
significant decrease in the amount of C3b detected at the GAS cell surface (P < 0.001) (Fig. 
2A). No signal was detected when GAS was incubated with 1% BSA alone (data not shown). 
To assess the impact of cell surface plasmin activity on C3b deposition, the isogenic GAS 
strain set were each transformed with an eGFP-expressing plasmid, opsonized with human 
plasma, and C3b deposition measured via flow cytometry. Significantly less C3b was 
detected at the surface of wild-type strain NS88.2, which accumulates plasmin(ogen) on its 
cell surface, than, NS88.2prp (P < 0.01), which does not accumulate plasmin(ogen) at the cell 
surface. However, no significant difference was seen in C3b deposition between NS88.2 and 
NS88.2∆ska (Fig. 2B). No significant fluorescence was detected using an isotype matched 
control antibody (data not shown).Cell surface plasmin acquisition assays confirmed that 
neither NS88.2prp  or NS88.2∆ska  bound significant levels of plasmin at the cell surface 
(Fig. 2C), suggesting that plasminogen binding rather than plasmin activation or acquisition 
is responsible for the decrease in C3b deposition. Western blot analysis of proteins eluted 
from the GAS cell surface confirmed that both NS88.2 and NS88.2∆ska, which showed 
decreased levels of C3b at the cell surface, bound plasminogen in human plasma, whilst 
NS88.2 prp, which was readily opsonised by C3b, did not (Fig. 2D).   
Plasminogen at the GAS cell surface impairs complement-mediated neutrophil killing 
One ultimate consequence of C3b deposition on microbial surfaces is phagocytosis and 
killing by neutrophils. Therefore, to further examine the functional significance of observed 
decreases in C3b deposition, bacteria were opsonized with human plasma and survival in the 
presence of human neutrophils measured. Wild-type strain NS88.2 was significantly more 
resistant to neutrophil killing compared to NS88.2prp (P < 0.05). No significant difference in 





(Fig. 3A).  To confirm that this observation was complement-dependent, the assay was 
repeated using complement-depleted plasma. No significant differences in survival of wild-
type and mutant GAS strains were observed in the absence of complement (Fig. 3B). 
Incubation of bacteria with Spectrozyme PL post-opsonization confirmed that wild-type 
NS88.2 sequestered significantly higher levels of cell surface plasmin than either the 
NS88.2prp (P < 0.001) or NS88.2∆ska (P < 0.01) mutants (Fig. 3C), supporting the 
hypothesis that increased survival does not correlate with plasmin acquisition.  
Plasmin(ogen) acquisition is associated with immune evasion in vivo 
To extend our investigation of the effect of GAS cell surface plasminogen acquisition on C3b 
deposition in vivo, an animal model of infection was established in mice expressing the 
human plasminogen transgene. Our previously published work indicated that mice 
heterozygous for the AlbPLG1 transgene are more susceptible to infection with GAS strain 
NS88.2 [5]. Here, we employed a homozygous mouse line, which expresses two copies of the 
AlbPLG1 gene. Both mouse lines expressed equivalent levels of mouse plasminogen (197.46 
+/- 19.37  µg/ml and 169.55 +/- 28.22 µg/ml for heterozygous and homozygous mice 
respectively).  Mice heterozygous for the AlbPLG1 transgene express approximately 17% the 
level of human plasminogen found in human plasma [19].  The level of activatable human 
plasminogen in the homozygous mouse line was found to be 34 % (+/- 2.3%) that of the level 
in human plasma.  Plasma from the homozygous mouse line displayed higher levels of 
streptokinase-mediated plasminogen activation, and resulted in increased cell surface plasmin 
acquisition by GAS compared with plasma from heterozygous mice (Fig. S2). Overall 
virulence of GAS strain NS88.2 was equivalent in the two mouse lines (Fig. S2). Cohorts of 
four sex matched mice aged between 8 and 10 weeks old were intradermally inoculated with 





of infection was lavaged 4 h post-inoculation, and C3b deposition analysed via flow 
cytometry. Significantly lower levels of C3b were detected at the surface of wild-type strain 
NS88.2 compared to mutant NS88.2prp (P < 0.001; Fig. 4A). The significance of decreased 
C3b deposition was further assessed by comparing the number of eGFP-positive neutrophils 
isolated from the flank 4 hours post-infection with eGFP-expressing NS88.2, NS88.2prp or 
NS88.2∆ska. NS88.2 prp showed significantly higher levels of association with neutrophils 
than NS88.2 or NS88.2 (P < 0.0001; Fig. 4B), suggesting that increased C3b deposition at the 
surface of this strain results in an increase in uptake by neutrophils.  Finally, we compared 
bacterial load following infection with wild-type and mutant GAS strains. A significantly 
higher bacterial load at the site of infection was seen for NS88.2 compared with NS88.2prp 
(P < 0.01), however there was no significant difference between the number of bacteria 
recovered for NS88.2 and NS88.2∆ska post-infection, as expected (P > 0.05) (Fig. 4C). The 
propensity to acquire cell surface plasmin(ogen) therefore correlates with reduced 
complement deposition and increased bacterial survival in vivo. To further investigate the 
mechanism behind our in vivo findings, we compared C3b deposition, cell surface plasmin 
acquisition and cell-surface plasminogen acquisition in vitro using humanised mouse plasma.  
Consistent with the findings of both the in vitro studies using human plasma and the in vivo 
findings, C3b deposition in mouse plasma was significantly lower for NS88.2 compared with 
NS88.2prp, but not NS88.2∆ska  (Fig.  5A). However, subsequent analysis of cell surface 
plasmin acquisition by GAS in mouse plasma revealed that NS88.2∆ska accumulated 
significantly higher levels of plasmin compared to NS88.2prp (P < 0.01; Fig. 5B). Western 
blot analysis of proteins eluted from the GAS cell surface confirmed that both NS88.2 and 
NS88.2∆ska, which showed decreased levels of C3b at the cell surface, bound  plasminogen 





The observed similarity in C3b deposition in vivo between NS88.2∆ska and the wild-type 
parent strain is may therefore also be due to cell either cell-surface plasmin or cell surface 






The ability of GAS to activate and sequester the host protease plasmin has been linked to 
bacterial dissemination and degradation of host tissue barriers during invasive disease 
initiation [3,7]. Here we demonstrate for the first time that plasmin(ogen) acquisition protects 
GAS from complement-mediated phagocytosis, and results in increased bacterial load during 
early infection. 
During the initial stages of infection, invading pathogens must overcome innate immune 
barriers, including the bactericidal effects of complement. C3b plays a central role in the 
innate immune response to bacterial infection, and opsonization of bacteria with C3b 
facilitates neutrophil phagocytosis. GAS have evolved numerous strategies to minimize 
complement deposition at the bacterial cell surface, including expression of M protein [20]. 
The presence of M6 and M49 at the GAS cell surface has been linked to protection from 
C3b-mediated phagocytosis [21], while fibrinogen and factor H binding by certain M 
serotypes has been shown to block C3b deposition at the bacterial cell surface [20]. To date, 
over 200 different M protein types have been identified, and M protein function is highly 
diverse [22]. This study defines a new role for plasminogen-binding M proteins in GAS 
resistance to phagocytosis.   
Plasmin exhibits broad spectrum protease activity, which is central to its involvement in 
inflammation, fibrinolysis and tissue remodelling [23]. However, these properties necessitate 
strict regulation of proteolysis under normal conditions. Secretion of streptokinase by GAS 
facilitates plasmin generation independent of host activators, while attachment of plasmin to 
the GAS cell surface protects plasmin from circulating inhibitors such as alpha-2-antiplasmin. 





This study shows that the ability of GAS strain NS88.2 to degrade C3b is dependent on the 
presence of cell surface plasmin activity however, data suggest that it is the ability of this 
strain to accumulate plasminogen at the cell surface, rather than plasmin,  that is protective 
against C3b-mediated phagocytosis. Minimal C3b degradation was seen following overnight 
incubation of GAS with C3b. This suggests that the activity of surface localised plasmin for 
soluble C3b is low. Interestingly, a number of studies looking at C3b degradation by surface 
localised plasmin show similar results, with intact C3b still visible after 24 h [24,25].  This 
may explain the findings in this study that there is limited correlation between cell-surface 
plasmin acquisition and C3b deposition. Subsequent in vitro analyses using human plasma 
indicated no correlation between cell-surface plasmin accumulation and C3b deposition at the 
GAS cell surface. Rather, decreased C3b deposition correlated with the ability of GAS to 
sequester plasminogen to the cell surface. However, assays performed using plasma from 
humanized plasminogen mice revealed that reduced C3b deposition correlates with both cell 
surface plasmin and cell surface plasminogen acquisition.  This may be indicative of 
differences between mouse plasma and human plasma, even in this humanized model. It is 
therefore difficult to rule out a role for plasmin acquisition in the in vivo model, and it may be 
that in this context, both plasminogen and plasmin at the GAS cell surface provide protection 
against C3b deposition.  Given the low level of  C3b degradation detected by surface- 
localized plasmin, it may be that surface-localised plasmin is more efficient at cleaving 
surface deposited C3b, and our data clearly show that soluble plasmin can facilitate the 
removal of C3b from the GAS cell surface. Alternatively, it has been shown that degradation 
of C3b by plasmin inhibits complement activation by preventing the formation of the C3 





the GAS cell surface blocks this pathway, and is responsible for the reduced levels of C3b 
deposition seen in vivo.  
Recently, it has been demonstrated that plasminogen binds to complement components C3, 
C3b and C3d, and when activated to plasmin by the host activator uPA, plasmin cleaves C3b, 
inhibits complement activation and prevents complement-mediated haemolysis of rabbit 
erythrocytes [26]. The cleavage fragments of C3b generated in this study using streptokinase 
activated plasminogen, or commercially obtained plasmin were found to be of a similar but 
not identical in size to those reported by Barthel et al. [26]. Differences in electrophoretic 
mobility may reflect different commercial sources of C3b, or differences in the length of time 
C3b was incubated with a plasmin source between the two studies. However, both the 
previous study and the current study indicate that surface localized plasmin degrades C3b.  
GAS is equipped with an array of virulence factors that together exert anti-phagocytic 
properties. Both M and M-like proteins have been linked to the survival of certain GAS 
strains inside human neutrophils and blood [27,28], while pore-forming streptolysin S and O 
exert cytotoxic activity on host neutrophils and impair their recruitment to the site of bacterial 
infection [29,30]. Furthermore, loss of the GAS surface hyaluronic acid capsule is also 
associated with decreased resistance to neutrophil phagocytosis and reduced virulence in 
mice [31]. Thus, GAS is protected from different stages of the innate immune response via 
co-ordinated expression of multiple virulence factors. This is reflected in the finding that 
even in the presence of cell surface plasmin(ogen), GAS strainNS88.2prp retains 
approximately 80% survival compared with the wild-type parent strain in our in vitro 
neutrophil killing assays. Nevertheless, an ability of GAS to co-opt plasmin(ogen) correlated 
to a significant increase in bacterial survival, and a decrease in association with neutrophils, 





Inactivation of C3b via cleavage into smaller, non-functional products as a result of plasmin 
activation has been described for several additional human pathogens including 
Staphylococcus aureus [11], Bacillus anthracis [32] and Borrelia burgdorferi [33]. However, 
to our knowledge, this is the first time this potential virulence mechanism has been linked to 
bacterial survival in vivo. The ability of GAS to initiate invasive disease has been shown to 
be dependent on cell surface plasmin acquisition [4,5] however, few studies of the role of 
plasminogen in GAS infection have looked at the early stages of disease, where the innate 
immune response is critical. Recently, it was shown that GAS mediated plasminogen 
activation facilitates protection from the antimicrobial peptide LL-37 [8]. The current study 
clearly demonstrates that, in addition to facilitating tissue degradation and bacterial 
dissemination, localization of plasmin at the GAS cell surface via the M protein is critical for 
bacterial survival in the early stages of infection. These data provide new insight into the 
antiphagocytic role of the GAS M protein, and add to our understanding of how plasminogen 
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Fig. 1. Streptokinase generated plasmin and GAS cell surface plasmin degrade 
C3b. In both panels, protein samples were resolved by SDS-PAGE under reducing 
conditions and transferred onto a nitrocellulose membrane. Cleavage of C3b was 
analysed via Western blotting using goat anti-C3 IgG and HRP-conjugated secondary 
antibody. A. Human C3b was incubated overnight singly (lane 1) or together with 
plasminogen (Plg) (lane 2); streptokinase (SK) (lane 3); human plasmin (lane 4); or a 
combination of plasminogen and streptokinase (lane 5). B. GAS were pre-incubated 
with (+) or without (-) 100 nM Glu-plasminogen for 2 h at 37°C, followed by 
incubation with 0.5 µg C3b overnight. Intact C3b is visible as the α-chain and the β-
chain (lane 1). Plasmin at the cell surface of NS88.2 partially cleaved C3b into smaller 
degradation products (lane 2). C3b remained intact and was not cleaved in the absence 
of plasmin at the cell surface of NS88.2 (lane 3), or when NS88.2prp or NS88.2∆ska 
was incubated with C3b (lanes 4-7). 














































































































Fig. 2. Plasmin(ogen) decreases C3b deposition on GAS in vitro. A. The impact of fluid-phase  plasmin on C3b 
deposition on the GAS cell surface was assessed using whole-cell ELISA. The addition of exogenous plasmin post-
bacterial opsonisation led to a significant decrease in C3b attachment to the bacterial surface (P < 0.001). B.IN order 
to assess the impact of cell-surface plasmin on C3b deposition,  bacteria were opsonized at 37°C for 10 min in 50% 
human plasma as a source of complement and plasmin(ogen). Non-specific binding sites were blocked by incubating 
bacteria with human IgG and surface-bound C3b was probed using phycoerythrin (PE)-conjugated monoclonal 
antibody raised against human C3. Alternatively, cells were stained with PE-labelled mouse IgG isotype control. C3b 
deposition on the bacterial surface was analysed using flow cytometry. C3b deposition was significantly reduced on 
the surface of NS88.2 compared to NS88.2prp (P < 0.01) , but not NS88.2Δska. Histograms show the shift in mean 
fluorescence intensity between GAS stained with the isotype control (grey) and an anti-C3 antibody (white). Bars 
indicate mean ± standard error of triplicates expressed in mean fluorescence intensity (MFI), representaive of  two 
independent experiments.  C. GAS cell surface plasmin activity was confirmed by incubating bacteria with the 
plasmin-specific substrate Spectrozyme-PL overnight. D. GAS cell surface plasminogen acquisition was confirmed by 
western-blot analysis of proteins eluted from the GAS cell surface following incubation in human plasma. Data is 












































Figure 3 Ly et al.   
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Fig. 3. Plasminogen at the GAS cell surface confers protection to C3b-mediated 
killing. Bacteria were opsonized with 50% human plasma for 10 min at 37°C as a 
source of plasminogen and complement. Washed bacteria were co-cultured with 
purified human neutrophils for 30 min at 37°C to allow for phagocytic uptake, with 
phagocytosis disrupted by hypotonic lysis of neutrophils. The numbers of viable 
bacterial colonies were enumerated after overnight incubation at 37°C. Negative 
controls consisted of bacteria incubated under the same conditions without neutrophils. 
A. NS88.2 was significantly more resistant to complement-mediated neutrophil killing 
than NS88.2prp (P < 0.05), but not  NS88.2∆ska. B. Bacteria were alternatively 
incubated with C3-depleted plasma. GAS strains showed no differences from 
neutrophil killing. C. Opsonized bacteria were also incubated with the plasmin-specific 
substrate Spectrozyme PL overnight to confirm levels of cell surface plasmin activity . 
Bars indicate mean ± standard error of triplicate determinations from three independent 




Figure 4 Ly et al.   
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Fig. 4. Plasmin(ogen) at the GAS cell surface is associated with immune evasion in 
an intradermal infection mouse model. Transgenic humanized plasminogen mice 
were inoculated with 1 X 108 CFU of eGFP-expressing GAS strains NS88.2, 
NS88.2prp or NS88.2∆ska via intradermal injection to the right and left flanks. Four 
hours post-infection, wound sites were lavaged with saline and the recovered 
supernatants collected. A. C3b deposition on the surface of NS88.2 was significantly 
reduced compared to NS88.2prp (P < 0.05), while C3b deposition levels were 
comparable between NS88.2 and NS88.2∆ska. Bars indicate mean ± standard error of 
duplicates in three independent experiments expressed in mean fluorescence intensity 
(MFI) for C3b deposition.  B. GAS strain NS88.2prp was phagocytosed by mouse 
neutrophils 4h post-infection when compared to NS88.2  or NS88.2∆ska  (P < 0.0001) 
C. A significantly lower bacterial load was obtained for NS88.2prp compared to 
NS88.2 and NS88.2∆ska (P < 0.01). Data is combined from four (NS88.2prp and 
NS88.2∆ska) and five (NS88.2) independent experiments, performed in duplicate. 
Asterisks indicate statistical significance ( ** P < 0.05; *** P < 0.0001),  ns indicates 
no significant difference. 





























































































Figure 5  Ly et al.   
Fig. 5. Plasmin(ogen) decreases C3b deposition on GAS in mouse plasma. A.In order to assess the impact of cell-
surface plasmin (ogen) on C3b deposition,  bacteria were opsonized at 37°C for 10 min in 50% mouse plasma as a 
source of complement and plasmin(ogen). Non-specific binding sites were blocked by incubating bacteria with human 
IgG and surface-bound C3b was probed using phycoerythrin (PE)-conjugated monoclonal antibody raised against 
human C3. Alternatively, cells were stained with PE-labelled mouse IgG isotype control. C3b deposition on the 
bacterial surface was analysed using flow cytometry. C3b deposition was significantly reduced on the surface of 
NS88.2 compared to NS88.2prp (P < 0.01) , but not NS88.2Δska. Histograms show the shift in mean fluorescence 
intensity between GAS stained with the isotype control (grey) and an anti-C3 antibody (white). Bars indicate mean ± 
standard error of triplicates expressed in mean fluorescence intensity (MFI), representative of  two independent 
experiments.  C. GAS cell surface plasmin activity was confirmed by incubating bacteria with the plasmin-specific 
substrate Spectrozyme-PL overnight. D. GAS cell surface plasminogen acquisition was confirmed by western-blot 
analysis of proteins eluted from the GAS cell surface following incubation in mouse plasma. Data is representative of 
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Fig. S1. In vitro characterisation of NS88.2, and the isogenic prp and ska deletion 
mutants. A. Growth of NS88.2, NS88.2prp and NS88.2∆ska. B. Western blot analysis 
of streptokinase secreted into culture supernatants. An arrow indicates the major 
immunoreactive band. C. NS88.2, NS88.2prp and NS88.2∆ska produce equivalent 
levels of hyaluronic acid capsule. D. GAS cell surface plasmin acquisition in culture 
supernatants with the addition of Glu-plasminogen. Data represents the mean ± standard 
error of two independent experiments performed in triplicate. Asterisks indicate 
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Fig. S2. Characterisation of homozygous humanized plasminogen mice. A. 
Streptokinase-mediated plasminogen activation and B. cell surface plasmin acquisition 
by NS88.2 in plasma collected from AlbPLG+/- (heterozygous; n = 1) and AlbPLG1+/+ 
(homozygous; n = 2) mice. Streptokinase-mediated plasminogen activation data 
represent the mean ± standard deviation of duplicate assays. Cell surface plasmin 
acquisition data represent the mean ± standard error of two independent experiments 
performed in triplicate. Asterisks indicate statistical significance, P < 0.001 (***). C. 
Cohorts of 10 age and sex matched AlbPLG1+/- or AlbPLG1+/+ mice were infected 
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Fig. S1. In vitro characterisation of NS88.2, and the isogenic prp and ska deletion 
mutants. A. Growth of NS88.2, NS88.2prp and NS88.2∆ska. B. Western blot analysis 
of streptokinase secreted into culture supernatants. An arrow indicates the major 
immunoreactive band. C. NS88.2, NS88.2prp and NS88.2∆ska produce equivalent 
levels of hyaluronic acid capsule. D. GAS cell surface plasmin acquisition in culture 
supernatants with the addition of Glu-plasminogen. Data represents the mean ± standard 
error of two independent experiments performed in triplicate. Asterisks indicate 
statistical significance, P < 0.001 (***). 
